Orthotopic liver transplantation using low-dose tacrolimus and sirolimus

Liver Transplantation

Volumn 7, Issue 8, 2001, Pages 701-708

  McAlister, Vivian C ^a   Peltekian, Kevork M ^a   Malatjalian, Dickran A ^a   Colohan, Shannon ^a   MacDonald, Sara ^a   Bitter Suermann, Hinrich ^a   MacDonald, Allan S ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; IMMUNOSUPPRESSIVE AGENT; LIPID; METHYLPREDNISOLONE; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG POTENTIATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; GRAFT SURVIVAL; HEPATIC ARTERY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LIPID METABOLISM; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECIPIENT; SURVIVAL;

EID: 0034892636     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2001.26510     Document Type: Article

References (20)

1. Cyclosporin A, FK506, rapamycin: The use of a quantitative analytic tool to discriminate immunosuppressive drug interactions
2. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
3. A worldwide, phase III, randomized, controlled safety and efficacy study of a sirolimus/cyclosporine regimen for the prevention of acute rejection in recipients of primary mismatched renal allografts
4. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent
5. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
6. Sirolimus: A potent new immunosuppressant for liver transplantation
7. Experience with the use of sirolimus in liver transplantation: Use in patients for whom calcineurin inhibitors are contraindicated
8. The use of sirolimus in liver transplant recipients
9. Sirolimus immunosuppression for liver transplantation in the presence of malignancy
10. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: A report of the United States FK506 Study Group
11. Evolution of cardiovascular risk after liver transplantation: A comparison of cyclosporine A and tacrolimus (FK506)
12. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells
13. Use of rapamycin for the suppression of alloimmune reactions in vivo: Schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions
14. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat
15. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey
16. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus
17. Early steroid withdrawal following liver transplantation-Two year follow up
18. Rapamycin: A bone-sparing immunosuppressant?
19. An immunoassay for the measurement of sirolimus
20. Analytical performance of microparticle enzyme immunoassay and HPLC-tandem mass spectrometry in the determination of sirolimus in whole blood